Search results
View Wellington Sun, M.D.’s profile on LinkedIn, a professional community of 1 billion members. Infectious disease physician-scientist with diverse expertise in medicine, science…
- 487
- Vaxcellerant LLC
- 509
- Washington DC-Baltimore Area
Dr. Sun joined the FDA from the CDC, where he led field and laboratory research on Dengue fever and West Nile virus, and was principal investigator of the first-ever controlled human infection trial in subjects previously vaccinated with tetravalent dengue vaccines.
Sep 6, 2018 · The company lured FDA official Wellington Sun, M.D., to help discover new candidates and advance existing programs. Sun will take the position of head of vaccine strategy and regulatory affairs...
- Eric Sagonowsky
Sep 5, 2018 · Moderna Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Dr. Wellington Sun will join the company as its Head, Vaccine Strategy and Regulatory Affairs, starting later this month.
Sep 15, 2018 · Moderna reported that Dr. Wellington Sun will join the company as its Head, Vaccine Strategy and Regulatory Affairs, starting later this month. Dr. Sun comes to Moderna from the U.S. Food and Drug Administration (FDA), where he was Director of the Division of Vaccines and Related Product Applications at the Center for Biologics Evaluation and ...
Author. Wellington Sun 1. Affiliation. 1 Vaxcellerant LLC, Silver Spring, MD, United States. Electronic address: wellington.sun@vaxcellerant.com. PMID: 37198023. DOI: 10.1016/j.vaccine.2023.05.008. Monkeypox, smallpox, FDA, and accelerated approval of vaccines - A regulatory perspective.
Wellington SUN | Cited by 4,675 | of Moderna, Cambridge (MODERNA) | Read 57 publications | Contact Wellington SUN
